Comparative study of Shugan Jieyu Capsules and Sertraline in treatment of mild and moderate depression in the elderly
ZHANG Xia1 LI Yunxia1 ZHANG Yan1 ZHANG Yuanyuan2 SUN Zhonghua1▲
1.Department of Hongshankou Outpatient, Jingbei Medical District, Chinese PLA General Hospital, Beijing 100091, China;
2.Department of Rehabilitation Medicine, People’s Liberation Army Hospital, 984th, Beijing 100094, China
Abstract：Objective To observe the clinical efficacy, adverse reactions and safety of Shugan Jieyu Capsules and Sertraline in the treatment of mild and moderate depression in the elderly. Methods Seventy-five cases of mild and moderate depression patients from April 2016 to October 2019 in the Department of Rehabilitation Medicine of the People’s Liberation Army Hospital, 984th and the Department of Hongshankou Outpatient of Jingbei Medical District of Chinese PLA General Hospital were selected, all patients in line with the Chinese classification and diagnostic criteria for mental disorders, aged ≥60 years, first onset cases. According to the random number table method, they were divided into the treatment group (Shugan Jieyu Capsules) with 38 cases and the control group (Sertraline) with 37 cases, a total of eight weeks of treatment and observation. The Hamilton Depression Scale 17 (HAMD-17), reduction rate, and treatment emergent symptom scale (TESS) were used to evaluate the efficacy and adverse reactions before treatment and at the end of the second, fourth and eighth week of treatment. Results The differences of time points and interaction between the two groups were highly statistically significant (all P ＜ 0.01), while the difference between the two groups was not statistically significant (P ＞ 0.05). Intra-group comparison: compared with before treatment, HAMD-17 scores in both groups decreased at two, four, and eight weeks after treatment, and the differences were statistically significant (P ＜ 0.05 or P ＜ 0.01). Comparison between groups: there was no statistically significant difference between the two groups in the same period (all P ＞ 0.05). There was no significant difference in total effective rate between the two groups (P ＞ 0.05). The incidence of adverse reactions in the treatment group was lower than that in the control group, with statistically significant difference (P ＜ 0.05). Conclusion Shugan Jieyu Capsules has the same efficacy as Sertraline in the treatment of mild and moderate depression in the elderly, and the adverse reactions are significantly less than Sertraline. It is an ideal choice for the treatment of mild and moderate depression in the elderly.
张霞1 李云霞1 张艳1 张媛媛2 孙中华1▲. 疏肝解郁胶囊与舍曲林治疗老年轻中度抑郁症对照研究[J]. 中国医药导报, 2020, 17(32): 116-119.
ZHANG Xia1 LI Yunxia1 ZHANG Yan1 ZHANG Yuanyuan2 SUN Zhonghua1▲. Comparative study of Shugan Jieyu Capsules and Sertraline in treatment of mild and moderate depression in the elderly. 中国医药导报, 2020, 17(32): 116-119.
[1] 高月霞，徐红，肖静，等.南通市老年人抑郁状况及其影响因素分析[J].中国老年学杂志，2012，32（1）：115-117.
[2] 张玲，徐勇，聂宏伟.2000～2010年中国老年人抑郁患病率的meta分析[J].中国老年学杂志，2011，31（17）：3349-3352.
[3] 中华医学会精神科学会.中国精神障碍分类与诊断标准[S].3版.济南：山东科学技术出版社，2001：87-88.
[4] 李凌江，马欣.中国抑郁障碍防治指南[M].2版.北京：中华医学电子音像出版社，2015：7-25.
[5] 江开达，马弘.中国精神疾病防治指南[M].北京：北京大学医学出版社，2010：72-78.
[6] Valiengo L，Casati R，Bolognini N，et al. Transcranial direct current stimulation for the treatment of post-stroke depression in aphasic patients：a case series [J]. Neurocase，2016，22（2）：225-228.
[7] 扈娜，刘堃.抑郁情绪在社区老年人自我感知老化与生命质量间的中介效应[J].护理研究，2019，33（1）：46-49.
[8] 万仁玲，潘绮，安晓虹，等.抑郁症小鼠模型的神经免疫改变[J].解剖学报，2018，49（3）：281-287.
[9] 叶增杰，梁木子，余远亮，等.老年抑郁症诊治的研究进展[J].医学与哲学，2017，38（6）：76-79，83.
[10] 白存海，于丽燕.舒肝解郁胶囊联合小剂量氯米帕明片治疗抑郁症的疗效研究[J].医学临床研究，2019，36（1）：101-102，105.
[11] 段海水，吕贝，赵玉林，等.舒肝解郁胶囊联合安非他酮治疗老年抑郁症的疗效观察[J].现代药物与临床，2017， 32（2）：289-292.
[12] 程旺强.疏肝解郁胶囊治疗脑卒中后抑郁50例[J].现代中西医结合杂志，2012，21（3）：304.
[13] 刘巧.舒肝解郁胶囊联合文拉法辛治疗抑郁症的效果分析[J].中外医学研究，2018，16（15）：128-129.
[14] Crupi R，Abusamra YA，Spina E，et a1. Preclinical data supporting/ refuting the use of Hypeficum perforatum in the treatment of depression [J].CNS Neurol Disord Drug Targets，2013，12（4）：474-486.
[15] Solomon D，Adams J，Graves N. Economic evaluation of St.John′s wort（Hypeficum perforatum）for the treatment of mild to moderate depression [J]. Affect Disord，2013， 148（2-3）：228-234.
[16] Sarris J，Fava M，Schweitzer I，et al. St John′s wort (Hypericum perforatum) versus sertraline and placebo in major depressive disorder：continuation data from a 26-week RCT [J]. Pharmacopsychiatry，2012，45（7）：275-278.
[17] 杨家豪，刘磊.舒肝解郁胶囊辅助治疗对老年抑郁症心理健康和预后的影响观察[J].临床研究，2020，28（3）：114-116.
[18] 吕扬，李峥，韩美英，等.门诊老年抑郁症患者服药依从性的影响因素分析[J].中华护理杂志，2015，50（10）：1203-1206.
[19] 傅锦华.新型抗抑郁中药舒肝解郁胶囊对抑郁模型大鼠的作用机制研究[D].长沙：中南大学，2014.
[20] 王含彦，郭冬梅，唐珍，等.舒肝解郁胶囊的抗抑郁作用及其机制[J].中成药，2018，40（1）：187-190.
[21] 罗金流.舒肝解郁胶囊联合文拉法辛治疗老年抑郁症的临床研究新进展[J].世界最新医学信息文摘，2016，16（91）：25-26.
[22] 邹卿，徐茜，杨紫君，等.舒肝解郁胶囊治疗老年抑郁症疗效与安全性的Meta分析[J].中国老年学杂志，2020， 40（1）：116-121.
[23] 中华医学会精神医学分会老年精神医学组.老年期抑郁障碍诊疗专家共识[J].中华精神科杂志，2017，50（5）：329-334.
[24] 黄玲，陈路佳，刘立立，等.舒肝解郁胶囊治疗轻、中度抑郁的疗效与安全性的系统评价[J].中国药房，2013， 24（32）：3043-3046.
[25] 谢敏敏，姜文海，杨海波.舒肝解郁胶囊治疗老年抑郁症的应用进展[J].医学综述，2015，1（22）：4119-4121.
2020, Vol. 17 
京公网安备 11010502046598号